Review of NICE Technology Appraisal Guidance No. 218; Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

The Institute was proposing that TA218 should be moved to the static list.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

TA218 will therefore be moved to the static list.  Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

April 2014

Attachments